Viridian Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Viridian Therapeutics Inc.
- Former names
- Miragen Therapeutics, INC. Signal Genetics, INC.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- VRDN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001590750
- EIN
- 47-1187261
Board of directors
-
Arlene Morris · DirectorSince 2023
-
Christopher W. Cain · DirectorSince 2025
-
Jeffrey Robert Ajer · DirectorSince 2025
-
Jennifer K. Moses · DirectorSince 2023
-
Jonathan Violin · Director · Chief Executive OfficerSince 2023
- Since 2023
-
Sarah Gheuens · DirectorSince 2023
-
Scott Dunseth Myers · Director · Chief Executive OfficerSince 2023
-
Stephen F. Mahoney · Director · President and CEOSince 2023
- Since 2023
Chief executives
Jonathan Violin
· Chief Executive Officer
Dates unknown
Scott Dunseth Myers
· Chief Executive Officer
Since February 2023
Stephen F. Mahoney
· President and CEO
Until February 2023
· Former
Director election results
Annual meeting of June 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
83.3%
-
99.5%
Board connections
7 of this board's directors also sit on 14 other boards.
- via Arlene Morris, Christopher W. Cain and Peter Evan Harwin
- via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
- via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
- via Christopher W. Cain, Peter Evan Harwin and Tomas Kiselak
- via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
- via Christopher W. Cain and Peter Evan Harwin
- via Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Scott Dunseth Myers
- via Arlene Morris
- via Jeffrey Robert Ajer
- via Arlene Morris
- via Scott Dunseth Myers
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $29,999,980
- 2 purchases by 2 insiders
- Sold, last 12 months
- $418,990
- 3 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 19, 2026 | Tousignant Jennifer Officer (Chief Legal Officer) | Open-market sale | −4,212 | $24.50 | $103,194 |
| Aug 19, 2026 | Tousignant Jennifer Officer (Chief Legal Officer) | Option exercise | +10,000 | $14.41 | $144,100 |
| Aug 19, 2026 | Tousignant Jennifer Officer (Chief Legal Officer) | Open-market sale | −10,000 | $24.50 | $245,000 |
| Aug 14, 2026 | Tripuraneni Radhika Officer (Chief Medical Officer) | Option exercise | +40,000 | $13.21 | $528,400 |
| May 11, 2026 | Fairmount Healthcare Fund II L.P. Director, 10% owner | Open-market purchase | +1,176,470 | $17.00 | $19,999,990 |
| Mar 3, 2026 | Tousignant Jennifer Officer (Chief Legal Officer) | Option exercise | +5,169 | — | — |
| Mar 3, 2026 | Harmon Seth Officer (Chief Financial Officer) | Option exercise | +6,267 | — | — |
| Mar 3, 2026 | Beetham Thomas W. Officer (Chief Operating Officer) | Option exercise | +9,409 | — | — |
| Mar 3, 2026 | Stephen F. Mahoney Officer (President and CEO) | Option exercise | +18,357 | — | — |
| Mar 3, 2026 | Tousignant Jennifer Officer (Chief Legal Officer) | Shares withheld for tax | −1,724 | $29.32 | $50,548 |
| Mar 3, 2026 | Harmon Seth Officer (Chief Financial Officer) | Shares withheld for tax | −2,091 | $29.32 | $61,308 |
| Mar 3, 2026 | Beetham Thomas W. Officer (Chief Operating Officer) | Shares withheld for tax | −3,138 | $29.32 | $92,006 |
| Mar 3, 2026 | Stephen F. Mahoney Officer (President and CEO) | Shares withheld for tax | −7,627 | $29.32 | $223,624 |
| Dec 31, 2025 | Tousignant Jennifer Officer (Chief Legal Officer) | Open-market sale | −2,272 | $31.16 | $70,796 |
| Oct 23, 2025 | Fairmount Healthcare Fund II GP LLC Director, 10% owner | Open-market purchase | +454,545 | $22.00 | $9,999,990 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.